Brind.

Johnson & Johnson Q3 Earnings Show Revenue Growth, But MedTech Weakness Persists

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Johnson & Johnson reported Q3 revenue of $25.4 billion, which was 5.9% higher than the same quarter last year, and earnings per share of $2.59, exceeding the consensus estimate. The company raised its full-year 2026 outlook to 6.7%–7.1% operational sales growth. However, MedTech grew only 2.5%, falling short of expectations.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

While overall revenue grew, the MedTech segment showed weakness outside the U.S. Management attributed this slowdown to competitive pressure, procurement changes in China, disruption in the Middle East, and a decline in AbioMed.

From tickerreport.com

Who's involved

  • Johnson & JohnsonReported Q3 earnings and raised full-year 2026 operational sales guidance.
  • AbioMedExperienced a 1.5% decline in MedTech sales due to market pressures.
  • Middle EastCited as a source of operational disruption affecting Johnson & Johnson's sales.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AbioMedSpeculative

    AbioMed could see reduced revenue due to competitive pressure and procurement changes cited by Johnson & Johnson.

  • Middle EastSpeculative

    Companies operating in the Middle East might face increased operational costs or supply chain disruptions affecting sales.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped